Advanced technologies for oral controlled release: Cyclodextrins for oral controlled release

AAPS PharmSciTech

Volumn 12, Issue 4, 2011, Pages 1276-1292

  Salústio, Paulo José ^a   Pontes, Patrícia ^a   Conduto, Claúdia ^a   Sanches, Inês ^a   Carvalho, Catarina ^a   Arrais, João ^a   Marques, Helena M Cabral ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

controlled release; cyclodextrin; inclusion complex; solid dosage forms; solubility

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; CARBAMAZEPINE; CURCUMIN; CYCLODEXTRIN; FLUFENAMIC ACID; FUROSEMIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; NANOPARTICLE; SILYMARIN;

CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; MICROCRYSTALLINE SUSPENSION; MUCOADHESION; NANOTECHNOLOGY; NONHUMAN; OSMOTIC PUMP; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 83555176034     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9690-2     Document Type: Review

References (150)

1. A Vyas S Saraf S Saraf 2008 Cyclodextrin based novel drug delivery systems J Incl Phenom Macrocycl Chem 62 23 42 1:CAS:528:DC%2BD1cXhtVOmtbnL 10.1007/s10847-008-9456-y
2. AS Hoffman 2008 The origins and evolution of "controlled" drug delivery systems J Control Release 132 153 63 18817820 1:CAS:528: DC%2BD1cXhsVensLvN 10.1016/j.jconrel.2008.08.012
3. C Rupp H Steckel BW Müller 2010 Solubilization of poorly water-soluble drugs by mixed micelles based on hydrogenated phosphatidylcholine Int J Pharm 395 272 80 20580793 1:CAS:528:DC%2BC3cXosF2it7g%3D 10.1016/j.ijpharm.2010.05.025
4. S Szejtli 1998 Introduction and general overview of cyclodextrin chemistry Chem Rev 98 1743 53 11848947 1:CAS:528:DyaK1cXksV2itrw%3D 10.1021/cr970022c
5. T Vasconcelos B Sarmento P Costa 2007 Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov Today 12 1068 75 18061887 1:CAS:528:DC%2BD2sXhsVSmurnF 10.1016/j.drudis.2007.09.005 (Pubitemid 350186132)
6. J Xiong J Guo L Huang B Meng Q Ping 2008 The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats Drug Dev Ind Pharm 34 65 72 18214757 1:CAS:528:DC%2BD1cXptlKmuw%3D%3D 10.1080/03639040701508292 (Pubitemid 351156965)
7. Y Liu C Sun Y Hao T Liang L Zheng S Wang 2010 Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles J Pharm Pharmaceut Sci 13 589 606 1:CAS:528:DC%2BC3MXjtlaquw%3D%3D
8. RL Carrier LA Miller I Ahmed 2007 The utility of cyclodextrins for enhancing oral bioavailability J Control Release 123 78 99 17888540 1:CAS:528:DC%2BD2sXhtFyku7fI 10.1016/j.jconrel.2007.07.018 (Pubitemid 47566400)
9. G Corti M Cirri F Maestrelli N Mennini P Mura 2008 Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-β-cyclodextrin Eur J Pharm Biopharm 68 303 9 17616379 1:CAS:528:DC%2BD1cXlsF2ktA%3D%3D 10.1016/j.ejpb.2007.06.004
10. J Králová Z Kejík T Břísa Poučkova A Král P Martásek V Král 2010 Porphyrin-cyclodextrin conjugates as a nanosystem for versatile drug delivery and multimodal cancer therapy J Med Chem 53 128 38 19950899 10.1021/jm9007278 1:CAS:528:DC%2BD1MXhsV2htbfP
11. EY Kim ZG Gao JS Park H Lee K Han 2002 rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery Int J Pharm 233 159 67 11897420 1:CAS:528:DC%2BD38Xhslymsbg%3D 10.1016/S0378-5173(01)00933-4 (Pubitemid 34230428)
12. B Haeberlin T Gengenbacher A Meinzer G Fricker 1996 Cyclodextrins-useful excipients for oral peptide administration? Int J Pharm 137 103 10 1:CAS:528:DyaK28Xktlemt7k%3D 10.1016/0378-5173(96)04499-7 (Pubitemid 26238517)
13. K Uekama F Hirayama T Irie 1998 Cyclodextrin drug carrier systems Chem Rev 98 2045 76 11848959 1:CAS:528:DyaK1cXksV2itr0%3D 10.1021/cr970025p (Pubitemid 128633447)
14. T Loftsson T Järvinen 1999 Cyclodextrins in ophthalmic drug delivery Adv Drug Deliv Rev 36 59 79 10.1016/S0169-409X(98)00055-6 (Pubitemid 29074477)
15. H Matsuda H Arima 1999 Cyclodextrins in transdermal and rectal delivery Adv Drug Deliv Rev 36 81 99 10837710 1:CAS:528:DyaK1MXksFeguw%3D%3D 10.1016/S0169-409X(98)00056-8 (Pubitemid 29074478)
16. T Loftsson M Másson HH Sigurdsson 2002 Cyclodextrins and drug permeability through semi-permeable cellophane membranes Int J Pharm 232 35 43 11790488 1:CAS:528:DC%2BD38XjvFeqsA%3D%3D 10.1016/S0378-5173(01)00895-X (Pubitemid 34076752)
17. N Zerrouk G Corti S Ancillotti F Maestrelli M Cirri P Mura 2006 Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability Eur J Pharm Biopharm 62 241 6 16226882 1:CAS:528:DC%2BD28Xit1Churo%3D 10.1016/j.ejpb.2005.08.010 (Pubitemid 43356571)
18. W Ling J Xuehua X Weijuan L Chenrui 2007 Complexation of tanshinone IIA with 2-hydroxypropyl-β-cyclodextrin: effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats Int J Pharm 341 58 67 10.1016/j.ijpharm.2007.03.046 1:CAS:528:DC%2BD2sXot1Cls7g%3D (Pubitemid 47090205)
19. G Pescitelli AR Bilia MC Bergonzi FF Vincieri L Di Bari 2010 Cyclodextrins as carriers for kavalactones in aqueous media: spectroscopic characterization of (S)-7,8-dihydrokavain and β-cyclodextrin inclusion complex J Pharm Biomed Anal 52 479 83 20185265 1:CAS:528:DC%2BC3cXjt1Kjs78%3D 10.1016/j.jpba.2010.01.037
20. K Nakanishi T Masukawa T Nadai K Yoshii S Okada K Miyajima 1996 Prolonged release of drug from triacetyl-β-CD complex for oral and rectal administration J Incl Phenom Macrocycl Chem 25 181 4 1:CAS:528: DyaK2sXislWksg%3D%3D 10.1007/BF01041565 (Pubitemid 126648450)
21. S Péroche G Degobert J-L Putauxc M-G Blanchin H Fessi H Parrot-Lopez 2005 Synthesis and characterisation of novel nanospheres made from amphiphilic perfluoroalkylthio-β-cyclodextrins Eur J Pharm Biopharm 60 123 31 15848064 10.1016/j.ejpb.2005.01.005 1:CAS:528:DC%2BD2MXjsVehsLY%3D (Pubitemid 40545868)
22. HS Ganapathy MY Lee C Park KT Lim 2008 Sustained release applications of a fluoroalkyl ester-functionalized amphiphilic cyclodextrin by inclusion complex formation with water-soluble drugs in supercritical carbon dioxide J Fluorine Chem 129 1162 6 1:CAS:528:DC%2BD1cXhsVSqurfM 10.1016/j.jfluchem.2008.09.005
23. Z Wang T Horikawa F Hirayama K Uekama 1993 Design and in-vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose J Pharm Pharmacol 45 942 6 7908033 1:CAS:528:DyaK2cXhtFKlu7g%3D 10.1111/j.2042-7158.1993.tb05631.x (Pubitemid 23362662)
24. F Hirayama K Uekama 1999 Cyclodextrin-based controlled drug release system Adv Drug Deliv Rev 36 125 41 10837712 1:CAS:528:DyaK1MXksFensw%3D%3D 10.1016/S0169-409X(98)00058-1 (Pubitemid 29074480)
25. CM Fernandes P Ramos AC Falcão FJ Veiga 2003 Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits J Control Release 88 127 34 12586510 1:CAS:528:DC%2BD3sXpvF2nuw%3D%3D 10.1016/S0168-3659(02)00465-0 (Pubitemid 36173958)
26. HS Woldum KL Larsen F Madsen 2008 Cyclodextrin controlled release of poorly water-soluble drugs from hydrogels Drug Deliv 15 69 80 18197526 1:CAS:528:DC%2BD1cXmtVCjsA%3D%3D 10.1080/10717540701829267
27. T Irie K Uekama 1997 Pharmaceutical applications of cyclodextrins 3. Toxicological issues and safety evaluation J Pharm Sci 86 147 61 9040088 1:CAS:528:DyaK2sXhtVOgsLY%3D 10.1021/js960213f (Pubitemid 27078377)
28. H Namazi S Bahrami AA Entezami 2005 Synthesis and controlled release of biocompatible prodrugs of β-cyclodextrin linked with PEG containing ibuprofen or indomethacin Iran Polym J 14 921 7 1:CAS:528:DC%2BD2MXhtlCjtLnM (Pubitemid 41787740)
29. D Duchêne D Wouessidjewe G Ponchel 1999 Cyclodextrins and carrier systems J Control Release 62 263 8 10518659 10.1016/S0168-3659(99)00046-2 (Pubitemid 29486506)
30. M Kamada F Hirayama K Udo H Yano H Arima K Uekama 2002 Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats J Control Release 82 407 16 12175753 1:CAS:528:DC%2BD38XlvFOrsrY%3D 10.1016/S0168-3659(02)00171-2 (Pubitemid 34880194)
31. Szejtli J. Cyclodextrin technology. Dordrecht: Kluwer Academic; 1988. p. 450.
32. G Wenz B-H Han A Müller 2006 Cyclodextrin rotaxanes and polyrotaxanes Chem Rev 106 782 817 16522009 1:CAS:528:DC%2BD28XhsVOmt7s%3D 10.1021/cr970027+
33. T Endo H Ueda 2004 Large ring cyclodextrins-recent progress FABAD J Pharm Sci 29 27 38 1:CAS:528:DC%2BD28XosFI%3D
34. H Taira H Nagase T Endo H Ueda 2006 Isolation, purification and characterization of large-ring cyclodextrins (CD36 CD39) J Incl Phenom Macrocycl Chem 56 23 8 1:CAS:528:DC%2BD28XhtFSit77F 10.1007/s10847-006-9055-8
35. J Szejtli 1992 The properties and potential uses of cyclodextrin derivatives J Incl Phenom Mol Recog Chem. 14 25 36 1:CAS:528:DyaK3sXhtlWrsL8%3D 10.1007/BF01041363
36. L Szente J Szejtli 1999 Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development Adv Drug Deliv Rev 36 17 28 10837706 1:CAS:528:DyaK1MXksFegtw%3D%3D 10.1016/S0169-409X(98)00092-1 (Pubitemid 29074474)
37. R Challa A Ahuja J Ali RK Khar 2005 Cyclodextrins in drug delivery: an updated review AAPS PharmSciTech 6 E329 57 16353992 10.1208/pt060243 (Pubitemid 41631739)
38. P Mura S Furlanetto M Cirri F Maestrelli G Corti S Pinzauti 2005 Interaction of naproxen with ionic cyclodextrins in aqueous solution and in the solid state J Pharm Biom Anal. 37 987 94 1:CAS:528:DC%2BD2MXjs1Kls70%3D 10.1016/j.jpba.2004.06.016 (Pubitemid 40614829)
39. CM Buchanan NL Buchanan KJ Edgar JL Little MG Ramsey KM Ruble VJ Wacher MF Wempe 2008 Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-β-cyclodextrin formulations Biomacromolecules 9 305 13 18072746 1:CAS:528:DC%2BD2sXhsVWgur7I 10.1021/bm700827h (Pubitemid 351201613)
40. M Roux B Perly F Djedaïni-Pilard 2007 Self-assemblies of amphiphilic cyclodextrins Eur Biophys J 36 861 7 17665188 1:CAS:528:DC%2BD2sXht1Cnsb7I 10.1007/s00249-007-0207-6 (Pubitemid 350045050)
41. Fromming K-H, Szejtli J. Cyclodextrins in pharmacy. Dordrecht: Kluwer Academic; 1994.
42. A Al-Omar S Abdou L De Robertis A Marsura C Finance 1999 Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line Bioorg Med Chem Lett 9 1115 20 10328296 1:CAS:528:DyaK1MXjtVKls7o%3D 10.1016/S0960-894X(99)00150-X (Pubitemid 29204668)
43. JJ García-Rodriguez J Torrado F Bolás 2001 Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes Parasite 8 S188 90 11484352
44. K Uekama 2004 Design and evaluation of cyclodextrin-based drug formulation Chem Pharm Bull 52 900 15 15304981 1:CAS:528:DC%2BD2cXmvVKktbg%3D 10.1248/cpb.52.900 (Pubitemid 41701863)
45. T Loftsson SB Vogensen C Desbos P Jansook 2008 Carvedilol: solubilization and cyclodextrin complexation: a technical note AAPS PharmSciTech 9 425 30 18431667 1:CAS:528:DC%2BC3cXnslGjt74%3D 10.1208/s12249-008-9055-7
46. K Uekama F Hirayama H Arima 2006 Recent aspect of cyclodextrin-based drug delivery system J Incl Phenom Macrocycl Chem 56 3 8 1:CAS:528: DC%2BD28XhtFSit7zM 10.1007/s10847-006-9052-y
47. K Dua MV Ramana UV Sara M Himaja A Agrawal V Garg K Pabreja 2007 Investigation of enhancement of solubility of norfloxacin β-cyclodextrin in presence of acidic solubilizing additives Curr Drug Deliv 4 21 5 17269914 1:CAS:528:DC%2BD2sXitlamtb8%3D 10.2174/156720107779314776 (Pubitemid 46066411)
48. GL Amidon H Lennernäs VP Shah JR Crison 1995 A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 413 20 7617530 1:CAS:528:DyaK2MXksVGqur8%3D 10.1023/A:1016212804288
49. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). August 2000 BP; http://www.fda.gov/cder/ guidance/index.htm. Accessed Jun 2010.
50. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), September 1997 CMC 8; http://www.fda.gov/cder/guidance/index.htm. Accessed Jun 2010.
51. Council of Europe. Dosage forms. In: European Pharmacopoeia, supplement 6.0, Council of Europe, Strasbourg; 2007. p. 717-53
52. MZI Khan 1996 Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities Int J Pharm 140 131 43 1:CAS:528:DyaK28XlsFWku7Y%3D 10.1016/0378-5173(96)04561-9 (Pubitemid 26292760)
53. V Lemesle-Lamache D Wouessidjewe M Chéron D Duchéne 1996 Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behaviour of salbutamol Int J Pharm 141 117 24 1:CAS:528:DyaK28XlvFGitb8%3D 10.1016/0378-5173(96)04624-8 (Pubitemid 26302918)
54. Y Ikeda K Kimura F Hirayama H Arima K Uekama 2000 Controlled release of a water soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives J Control Release 66 271 80 10742586 1:CAS:528:DC%2BD3cXhvF2ksrs%3D 10.1016/S0168-3659(99)00286-2 (Pubitemid 30160863)
55. Y Ikeda S Motoune A Marumoto Y Sonoda F Hirayama H Arima K Uekama 2002 Effect of 2-hydroxypropyl-β-cyclodextrin on release rate of metoprolol from ternary metoprolol/2-hydroxypropyl-β-cyclodextrin/ethylcellulose tablets J Incl Phenom Macrocycl Chem 44 141 4 1:CAS:528:DC%2BD3sXkvFCqur0%3D 10.1023/A:1023082226992 (Pubitemid 38075679)
56. M Jug M Bécirevi-Laan 2004 Influence of hydroxypropyl-β- cyclodextrin complexation on piroxicam release from buccoadhesive tablets Eur J Pharm Sci 21 251 60 14757497 1:CAS:528:DC%2BD2cXptFWrtg%3D%3D 10.1016/j.ejps.2003.10.029 (Pubitemid 38156162)
57. B Pose-Vilarnovo C Rodríguez-Tenreiro Rosa dos Santos JF J Vázquez-Doval A Concheiro C Alvarez-Lorenzo JJ Torres-Labandeira 2004 Modulating drug release with cyclodextrins in hydroxypropyl methylcellulose gels and tablets J Control Release 94 351 63 14744486 1:CAS:528: DC%2BD2cXmtFCqsw%3D%3D 10.1016/j.jconrel.2003.10.002 (Pubitemid 38117146)
58. A Miro A Rondinone A Nappi F Ungaro F Quaglia MI La Rotonda 2009 Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: role of cyclodextrins and implications in oral drug delivery Eur J Pharm Biopharm 72 76 82 19135532 1:CAS:528:DC%2BD1MXjvVOqtL0%3D 10.1016/j.ejpb.2008.12.006
59. L Ribeiro DC Ferreira FJB Veiga 2005 In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets J Control Release 103 325 39 15763617 1:CAS:528: DC%2BD2MXitV2hsbw%3D 10.1016/j.jconrel.2004.12.001 (Pubitemid 40347295)
60. C Rodriguez-Tenreiro C Alvarez-Lorenzo A Rodriguez-Perez A Concheiro JJ Torres-Labandeira 2007 Estradiol sustained release from high affinity cyclodextrin hydrogels Eur J Pharm Biopharm 66 55 62 17081737 1:CAS:528:DC%2BD2sXjt1SksLw%3D 10.1016/j.ejpb.2006.09.003 (Pubitemid 46412967)
61. AL Nielsen F Madsen KL Larsen 2009 Cyclodextrin modified hydrogels of PVP/PEG for sustained drug release Drug Deliv 16 92 101 19267300 1:CAS:528:DC%2BD1MXktVWrtLs%3D 10.1080/10717540802605129
62. F Frézard PS Martins AP Bahia L Le Moyec AL Melo AM Pimenta M Salerno JB Silva C Demicheli 2008 Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies Int J Pharm 347 102 8 17656054 10.1016/j.ijpharm.2007.06.029 1:CAS:528:DC%2BD2sXhtlOjsrjN (Pubitemid 350186086)
63. N Özdemir S Ordu Y Özkan 2000 Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations Drug Dev Ind Pharm 26 857 66 10900542 10.1081/DDC-100101309 (Pubitemid 30451825)
64. Shishu N Gupta N Aggarwal 2008 Bioavailability enhancement and targeting of stomach tumors using gastro-retentive floating drug delivery system of curcumin-"a technical note" AAPS PharmSciTech 9 810 3 18600460 1:CAS:528:DC%2BC3cXovVKgt78%3D 10.1208/s12249-008-9096-y
65. R Garg GD Gupta 2009 Preparation and evaluation of gastroretentive floating tablets of silymarin Chem Pharm Bull 57 545 9 19483331 1:CAS:528:DC%2BD1MXpvVylsL0%3D 10.1248/cpb.57.545
66. HH Sigurdsson E Knudsen T Loftsson N Leeves JF Sigurjonsdotir M Másson 2002 Mucoadhesive sustained drug delivery system based on cationic polymer and anionic cyclodextrin/triclosan complex J Incl Phenom Macrocycl Chem 44 169 72 1:CAS:528:DC%2BD3sXkvFCqurc%3D 10.1023/A:1023098730627 (Pubitemid 38075685)
67. JP Venter AF Kotzé R Auzély-Velty M Rinaudo 2006 Synthesis and evaluation of the mucoadhesivity of a CD chitosan derivative Int J Pharm 313 36 42 16476531 1:CAS:528:DC%2BD28XjtVGquro%3D 10.1016/j.ijpharm.2006.01.016
68. M Prabaharan S Gong 2008 Novel thiolated carboxymethyl chitosan-g-β-cyclodextrin as mucoadhesive hydrophobic drug delivery carriers Carbohydr Polym 73 117 25 1:CAS:528:DC%2BD1cXjvVegtLY%3D 10.1016/j.carbpol.2007.11.005
69. M Jug F Maestrelli M Bragagnib P Mura 2010 Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery J Pharm Biom Anal 52 9 18 1:CAS:528:DC%2BC3cXhtVamtr0%3D 10.1016/j.jpba.2009.11.013
70. P Mura G Corti M Cirri F Maestrelli N Mennini M Bragagni 2010 Development of mucoadhesive films for buccal administration of flufenamic acid: effect of cyclodextrin complexation J Pharm Sci 99 3019 29 20127823 1:CAS:528: DC%2BC3cXlsVSku70%3D
71. 7m-β-cyclodextrin as both a solubilizing and an osmotic pump agent J Control Release 58 29 38 10021487 1:CAS:528:DyaK1MXhtFWnsrk%3D 10.1016/S0168-3659(98)00142-4 (Pubitemid 29371811)
72. 7m -β-CD as both a solubilizer and osmotic agent J Control Release 60 311 9 10425336 1:CAS:528: DyaK1MXks1Gjs74%3D 10.1016/S0168-3659(99)00077-2 (Pubitemid 29335956)
73. EA Zannou WH Streng VJ Stella 2001 Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins Pharm Research 18 1226 31 1:CAS:528: DC%2BD3MXnt1ektLo%3D 10.1023/A:1010947631380 (Pubitemid 32900410)
74. 7m-β-CD in controlled-porosity osmotic pump tablets (OPTs) Int J Pharm 286 81 8 15501004 1:CAS:528:DC%2BD2cXovVSksbY%3D 10.1016/j.ijpharm.2004.08.002 (Pubitemid 39410475)
75. 7m-β-CD, as a solubilizing and osmotic agent J Pharm Sci 96 2364 74 17497739 1:CAS:528:DC%2BD2sXhtVWntLbL 10.1002/jps.20891 (Pubitemid 47477892)
76. S Sotthivirat JL Haslam PI Lee VM Rao VJ Stella 2009 Release mechanisms of a sparingly water-soluble drug from controlled porosity-osmotic pump pellets using sulfobutylether-β-cyclodextrin as both a solubilizing and osmotic agent J Pharm Sci 98 1992 2000 18823032 1:CAS:528:DC%2BD1MXltleltbg%3D 10.1002/jps.21567
77. 7m-β-cyclodextrin as a solubilizing agent J Pharm Sci 90 807 16 11458330 1:CAS:528: DC%2BD3MXlt1Cqu7w%3D 10.1002/jps.1034 (Pubitemid 32645939)
78. G Trapani A Lopedota G Boghetich A Latrofa M Franco E Sanna G Liso 2003 Encapsulation and release of the hypnotic agent zolpidem from biodegradable polymer microparticles containing hydroxypropyl-β-cyclodextrin Int J Pharm 268 47 57 14643976 1:CAS:528:DC%2BD3sXptFGqs7Y%3D 10.1016/j.ijpharm.2003.08.016 (Pubitemid 37487822)
79. 7-β- cyclodextrin complexation on carbamazepine release from sustained release beads Eur J Pharm Biopharm 60 73 80 15848059 1:CAS:528:DC%2BD2MXjsVehtr8%3D 10.1016/j.ejpb.2004.12.001 (Pubitemid 40545863)
80. R Cavalli F Trotta M Trotta L Pastero D Aquilano 2007 Effect of alkylcarbonates of γ-cyclodextrins with different chain lengths on drug complexation and release characteristics Int J Pharm 339 197 204 17418510 1:CAS:528:DC%2BD2sXntFejs7s%3D 10.1016/j.ijpharm.2007.03.001 (Pubitemid 46977608)
81. L Trichard E Fattal M Besnard A Bochot 2007 α-Cyclodextrin/oil beads as a new carrier for improving the oral bioavailability of lipophilic drugs J Control Release 122 47 53 17629584 1:CAS:528:DC%2BD2sXpsV2rtb8%3D 10.1016/j.jconrel.2007.06.004 (Pubitemid 47284552)
82. M Yoshinari K Matsuza S Hashimoto K Ishihara T Inoue Y Oda T Ide T Tanaka 2007 Controlled release of simvastatin acid using cyclodextrin inclusion system Dent Mater J 26 451 6 17694757 1:CAS:528:DC%2BD2sXptFGmur4%3D 10.4012/dmj.26.451
83. H Blode R Schürmann N Benda 2008 Novel ethinyl estradiol-beta- cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone Contraception 77 171 6 18279686 1:CAS:528:DC%2BD1cXitVegsr8%3D 10.1016/j.contraception.2007.10.009
84. Y Zhou Z Guo Y Zhang W Huang Y Zhou D Yan 2009 Hyperbranched polyamidoamines containing β-cyclodextrin for controlled release of chlorambucil Macromol Biosci 9 1090 7 19603385 1:CAS:528:DC%2BD1MXhtlOku73K 10.1002/mabi.200900110
85. 2-assisted technology Int J Pharm 376 110 5 19409460 1:CAS:528:DC%2BD1MXntFynsbY%3D 10.1016/j.ijpharm.2009.04.029
86. H Yano F Hirayama M Kamada H Arima K Uekama 2002 Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administration J Control Release. 79 103 12 11853922 1:CAS:528:DC%2BD38XhtlSls7Y%3D 10.1016/S0168-3659(01)00532-6 (Pubitemid 34164164)
87. M-J Zou G Cheng H Okamoto X-H Hao F An F-D Cui K Danjo 2005 Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of five aminosalicylic acid from its cyclodextrin conjugates World J Gastroenterol 11 7457 60 16437716 1:CAS:528:DC%2BD28Xhs1antLo%3D (Pubitemid 43126026)
88. K Udo K Hokonohara K Motoyama H Arima F Hirayama K Uekama 2010 5-Fluorouracil acetic acid/β-cyclodextrin conjugates: drug release behaviour in enzymatic and rat cecal media Int J Pharm 388 95 100 20036722 1:CAS:528:DC%2BC3cXit1Sgt7g%3D 10.1016/j.ijpharm.2009.12.039
89. K Minami F Hirayama K Uekama 1998 Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration J Pharm Sci 87 715 20 9607948 1:CAS:528:DyaK1cXivVOlu78%3D 10.1021/js9704339 (Pubitemid 28268570)
90. X-M Liu H-T Lee RA Reinhardt LA Marky D Wang 2007 Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity J Control Release. 122 54 62 17673326 1:CAS:528:DC%2BD2sXpsV2rtbw%3D 10.1016/j.jconrel.2007.06.021 (Pubitemid 47284559)
91. ME Zugasti A Zornoza MM Goñi JR Isasi I Vélaz C Martín M Sánchez MC Martínez-Ohárriz 2009 Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets Drug Dev Ind Pharm 35 1264 70 19555243 1:CAS:528:DC%2BD1MXhtFKkt7jI 10.1080/03639040902882306
92. R Stancanelli V Crupi L De Luca P Ficarra R Ficarra R Gitto M Guardo N Iraci D Majolino S Tommasini V Venuti 2008 Improvement of water solubility of non-competitive AMPA receptor antagonists by complexation with β-cyclodextrin Bioorg Med Chem 16 8706 12 18762428 1:CAS:528: DC%2BD1cXhtFantLnL 10.1016/j.bmc.2008.07.085
93. A Trapani M Garcia-Fuentes MJ Alonso 2008 Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan Nanotechnology 19 1 10 10.1088/0957-4484/19/18/185101 1:CAS:528:DC%2BD1cXnsFWgsrc%3D (Pubitemid 351588178)
94. J Cheng KT Khin GS Jensen A Liu ME Davis 2003 Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates Bioconjug Chem 14 1007 17 13129405 1:CAS:528:DC%2BD3sXms1Kjtbw%3D 10.1021/bc0340924 (Pubitemid 37152961)
95. R Cavalli E Peira O Caputo MR Gasco 1999 Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins Int J Pharm 182 59 69 10332075 1:CAS:528:DyaK1MXjtVyksrg%3D 10.1016/S0378- 5173(99)00066-6 (Pubitemid 29229795)
96. D Duchêne G Ponchela D Wouessidjewen 1999 Cyclodextrins in targeting: application to nanoparticles Adv Drug Deliv Rev 36 29 40 10837707 10.1016/S0169-409X(98)00053-2 (Pubitemid 29074475)
97. Y Tozuka A Wongmekiat K Sakata K Moribe T Oguchi K Yamamoto 2004 Co-grinding with cyclodextrin as a nanoparticle preparation method of a poorly water soluble drug J Incl Phenom Macrocycl Chem 50 67 71 1:CAS:528: DC%2BD2cXptVejtLo%3D (Pubitemid 40137320)
98. N Mourtzis K Eliadou C Aggelidou V Sophianopoulou IM Mavridis K Yannakopoulou 2007 Per(6guanidino-6-deoxy)cyclodextrins: synthesis, characterization and binding behaviour toward selected small molecules and DNA Org Biomol Chem 5 125 31 17164916 1:CAS:528:DC%2BD28XhtlaitLbJ 10.1039/b614899a (Pubitemid 44927110)
99. Y-Z Du J-G Xu L Wang H Yuan F-Q Hu 2009 Preparation and characteristics of hydroxypropyl-β-cyclodextrin polymeric nanocapsules loading nimodipine Eur Polym J 45 1397 402 1:CAS:528:DC%2BD1MXkslOrtbo%3D 10.1016/j.eurpolymj.2009. 01.031
100. S Sajeesh CP Sharma 2006 Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery Int J Pharm 325 147 54 16859846 1:CAS:528:DC%2BD28XhtFSgsrrJ 10.1016/j.ijpharm.2006.06.019 (Pubitemid 44573692)
101. N Zhang J Li W Jiang C Ren J Li J Xin K Li 2010 Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles Int J Pharm 393 212 8 20394813 1:CAS:528:DC%2BC3cXms1elsbw%3D 10.1016/j.ijpharm.2010.04.006
102. M Agüeros P Areses MA Campanero H Salman G Quincoces I Peñuelas JM Irache 2009 Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles Eur J Pharm Sci 37 231 40 19491010 10.1016/j.ejps.2009.02.010 1:CAS:528:DC%2BD1MXms1Oksrk%3D
103. M Agüeros V Zabaleta S Espuelas MA Campanero JM Irache 2010 Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles J Control Release 145 2 8 20347897 10.1016/j.jconrel.2010.03.012 1:CAS:528: DC%2BC3cXms1emu7k%3D
104. P Jansook SV Kurkov T Loftsson 2010 Cyclodextrins as solubilizers: formation of complex aggregates J Pharm Sci 99 719 29 19670293 1:CAS:528:DC%2BD1MXhsF2jsLrN
105. T Yamanoi N Yoshida Y Oda E Akaike M Tsutsumida N Kobayashi K Osumi K Yamamoto K Fujita K Takahashi K Hattori 2005 Synthesis of mono-glucose branched cyclodextrins with a high inclusion ability for doxorubicin and their efficient glycosylation using Mucor hiemalis endo-β-N-acetylglucosaminidase Bioorg Med Chem Lett 15 1009 13 15686902 1:CAS:528:DC%2BD2MXos1CisA%3D%3D 10.1016/j.bmcl.2004.12.040 (Pubitemid 40458639)
106. V Burckbuchler V Wintgens C Leborgne S Lecomte N Leygue D Scherman A Kichler C Amiel 2008 Development and characterization of new cyclodextrin polymer-based DNA delivery systems Bioconjug Chem 19 2311 20 19053313 1:CAS:528:DC%2BD1cXhsVWks7rK 10.1021/bc800070f
107. X Lu Y Ping FJ Xu ZH Li QQ Wang JH Chen WT Yang GP Tang 2010 Bifunctional conjugates comprising β-cyclodextrin, polyethylenimine, and 5-fluoro-2′-deoxyuridine for drug delivery and gene transfer Bioconjug Chem 21 1855 63 20853891 1:CAS:528:DC%2BC3cXhtFOru7fO 10.1021/bc1002136
108. AK Upadhyay S Singh RR Chhipa MV Vijayakumar AK Ajay MK Bhat 2006 Methyl-β-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-κB and Bcl-2 Toxicol Appl Pharmacol 216 177 85 16806341 1:CAS:528:DC%2BD28XhtVWqtL%2FK 10.1016/j.taap.2006.05.009 (Pubitemid 44479786)
109. T Higashi F Hirayama S Misumi H Arima K Uekama 2008 Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system Biomaterials 29 3866 71 18620750 1:CAS:528:DC%2BD1cXpt1ems7g%3D 10.1016/j.biomaterials.2008.06.019
110. T Higashi F Hirayama S Yamashita S Misumi H Arima K Uekama 2009 Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with cyclodextrins Int J Pharm 374 26 32 19446755 1:CAS:528:DC%2BD1MXlvFGlt7Y%3D 10.1016/j.ijpharm.2009.02.017
111. C Cannavà V Crupi P Ficarra M Guardo D Majolino A Mazzaglia R Stancanelli V Venuti 2010 Physico-chemical characterization of an amphiphilic cyclodextrin/genistein complex J Pharm Biomed Anal 51 1064 8 20036091 10.1016/j.jpba.2009.11.025 1:CAS:528:DC%2BC3cXps1Gq
112. W Sajomsang P Gonil UR Ruktanonchai N Pimpha I Sramala O Nuchuchua S Saesoo S Chaleawlert-umpon S Puttipipatkhachorn 2011 Self-aggregates formation and mucoadhesive property of water-soluble β-cyclodextrin grafted with chitosan Int J Biol Macromol 48 589 95 21300088 1:CAS:528:DC%2BC3MXksFynu7o%3D 10.1016/j.ijbiomac.2011.01.028
113. C-Y Chen F-A Chen A-B Wu H-C Hsu J-J Kang H-W Cheng 1996 Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in-vitro permeability of alkannin/shikonin enantiomers Int J Pharm 141 171 8 1:CAS:528:DyaK28XlvFGiurw%3D 10.1016/0378-5173(96)04634-0 (Pubitemid 26302923)
114. S Tommasini ML Calabrò D Raneri P Ficarra R Ficarra 2004 Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin J Pharm Biom Anal 36 327 33 1:CAS:528:DC%2BD2cXovV2htLc%3D 10.1016/j.jpba.2004. 06.013 (Pubitemid 39371077)
115. K Terao D Nakata H Fukumi G Schmid H Arima F Hirayama K Uekama 2006 Enhancement of oral bioavailability of coenzyme Q10 by complexation with γ-cyclodextrin in healthy adults Nutrition Res 26 503 8 1:CAS:528:DC%2BD28XhtVygsbnI 10.1016/j.nutres.2006.08.004 (Pubitemid 44548091)
116. Z Lu B Cheng Y Hub Y Zhang G Guolin Zou 2009 Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity Food Chem 113 17 20 1:CAS:528:DC%2BD1cXhtF2ntLfK 10.1016/j.foodchem.2008.04.042
117. K Motoyama K Nagamoto SO Abd Elazim F Hirayama K Uekama H Arima 2009 Potential use of 2-hydroxypropyl-β-cyclodextrin for preparation of orally disintegrating tablets containing dl-alpha-tocopheryl acetate, an oily drug Chem Pharm Bull 57 1206 12 19881268 1:CAS:528:DC%2BC3cXhs1Kjsw%3D%3D 10.1248/cpb.57.1206
118. P Mura G Bettinetti F Melani A Manderioli 1995 Interaction between naproxen and chemically modified β-cyclodextrins in the liquid and solid state Eur J Pharm Sci 3 347 55 1:CAS:528:DyaK2MXpvVyqtbY%3D 10.1016/0928- 0987(95)00025-X
119. P Mura GP Bettinetti A Manderioli MT Faucci G Bramanti M Sorrenti 1998 Interactions of ketoprofen and ibuprofen with β-cyclodextrins in solution and in the solid state Int J Pharm 166 189 203 1:CAS:528:DyaK1cXjslGltrw%3D 10.1016/S0378-5173(98)00035-0 (Pubitemid 28255226)
120. M Charoenchaitrakool F Dehghani NR Foster 2002 Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin Int J Pharm 239 103 12 12052695 1:CAS:528: DC%2BD38XktFektro%3D 10.1016/S0378-5173(02)00078-9 (Pubitemid 34615799)
121. BN Naidu KP Chowdary KV Murthy V Satyanarayana AR Hayman G Becket 2004 Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems J Pharm Biom Anal 35 75 86
122. 2 J Supercrit Fluids 39 435 43 10.1016/j.supflu. 2006.02.009 1:CAS:528:DC%2BD28XhtF2js7rJ (Pubitemid 44711986)
123. M Fukuda DA Miller NA Peppas JW McGinity 2008 Influence of sulfobutyl ether β-cyclodextrin (Captisol®) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion Int J Pharm 350 188 96 17920217 1:CAS:528:DC%2BD1cXhtlGntb8%3D 10.1016/j.ijpharm.2007.08.038
124. M Cirri F Maestrelli N Mennini P Mura 2009 Physical-chemical characterization of binary and ternary systems of ketoprofen with cyclodextrins and phospholipids J Pharm Biom Anal 50 683 9 1:CAS:528:DC%2BD1MXhtF2ht7nL 10.1016/j.jpba.2008.11.003
125. M Sauceau E Rodier J Fages 2008 Preparation of inclusion complex of piroxicam with cyclodextrin by using supercritical carbon dioxide J Supercrit Fluids. 47 326 32 1:CAS:528:DC%2BD1cXht1Oks7bE 10.1016/j.supflu.2008.07.006
126. PJ Salústio G Feio JL Figueirinhas JF Pinto HM Cabral Marques 2009 The influence of the preparation methods on the inclusion of model drugs in a β-cyclodextrin cavity Eur J Pharm Biopharm 71 377 86 18977436 10.1016/j.ejpb.2008.09.027 1:CAS:528:DC%2BD1MXitVShtrk%3D
127. Y Lu X Zhang J Lai Z Yin W Wu 2009 Physical characterization of meloxicam-β-cyclodextrin inclusion complex pellets prepared by a fluid-bed coating method Particuology 7 1 8 10.1016/j.partic.2008.11.004 1:CAS:528:DC%2BD1MXktFKit7s%3D
128. MT Esclusa-Díaz M Gayo-Otero MB Pérez-Marcos JL Vila-Jato JJ Torres-Labandeira 1996 Preparation and evaluation of ketoconazole-β- cyclodextrin multicomponent complexes Int J Pharm 142 183 7 10.1016/0378- 5173(96)04666-2 (Pubitemid 26354644)
129. P Mura MT Faucci A Manderioli G Bramanti 1999 Influence of the preparation method on the physicochemical properties of binary systems of econazole with cyclodextrins Int J Pharm 193 85 95 10581425 1:CAS:528: DyaK1MXnsF2htL4%3D 10.1016/S0378-5173(99)00326-9
130. S-Y Lee I-I Jung J-K Kim G-B Lim J-H Ryu 2008 Preparation of itraconazole/HP-β-CD inclusion complexes using supercritical aerosol solvent extraction system and their dissolution characteristics J Supercrit Fluids 44 400 8 1:CAS:528:DC%2BD1cXjtlSktbw%3D 10.1016/j.supflu.2007.09.006 (Pubitemid 351324076)
131. JR Moyano JM Ginés MJ Arias AM Rabasco 1995 Study of the dissolution characteristics of oxazepam via complexation with β-cyclodextrin Int J Pharm 114 95 102 1:CAS:528:DyaK2MXivVKrtrg%3D 10.1016/0378-5173(94)00220-Y (Pubitemid 24377033)
132. HA Archontaki MV Vertzoni MH Athanassiou-Malaki 2002 Study on the inclusion complexes of bromazepam with β- and β-hydroxypropyl- cyclodextrins J Pharm Biom Anal 28 761 9 1:CAS:528:DC%2BD38Xjtl2nsr0%3D 10.1016/S0731-7085(01)00679-3 (Pubitemid 34465642)
133. AC Jain MC Adeyeye 2001 Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether β-cyclodextrins (SBE) and danazol-SBE inclusion complexes Int J Pharm 212 177 86 11165075 1:CAS:528:DC%2BD3MXmvFKksw%3D%3D 10.1016/S0378-5173(00)00607-4 (Pubitemid 32119443)
134. 7m-β-CD) and hydroxypropyl-β- cyclodextrin (HP-β-CD) complexation Int J Pharm 165 69 78 1:CAS:528:DyaK1cXis1Wqsr4%3D 10.1016/S0378-5173(98)00004-0 (Pubitemid 28218345)
135. A Latrofa G Trapani M Franco M Serra M Muggironi FP Fanizzi A Cutrignelli G Liso 2001 Complexation of phenytoin with some hydrophilic cyclodextrins: effect on aqueous solubility, dissolution rate, and anticonvulsant activity in mice Eur J Pharm Biopharm 52 65 73 11438425 1:CAS:528:DC%2BD3MXkvVeksLk%3D 10.1016/S0939-6411(01)00144-8 (Pubitemid 32594789)
136. M Echezarreta-López JJ Torres-Labandeira L Castiñeiras-Seijo L Santana-Penín JL Vila-Jato 2000 Complexation of the interferon inducer, bropirimine, with hydroxypropyl-β-cyclodextrin Eur J Pharm Sci 9 381 6 10664478 10.1016/S0928-0987(99)00081-0 (Pubitemid 30069529)
137. R Ficarra P Ficarra MR Di Bella D Raneri S Tommasini ML Calabrò A Villari S Coppolino 2000 Study of the inclusion complex of atenolol with β-cyclodextrins J Pharm Biom Anal 23 231 6 1:CAS:528:DC%2BD3cXktlCrtLo%3D 10.1016/S0731-7085(00)00274-0 (Pubitemid 30394572)
138. N Patel N Chotai J Patel T Soni J Desai R Patel 2008 Comparison of in vitro dissolution profiles of oxcarbazepine-HP-β-CD tablet formulations with marketed oxcarbazepine tablets Dissolution Tech 15 28 34 1:CAS:528:DC%2BD1MXhtVWrsrk%3D
139. H Hamada K Ishihara N Masuoka K Mikuni N Nakajima 2006 Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins J Biosci Bioeng 102 369 71 17116587 1:CAS:528:DC%2BD28Xhtlemsr3J 10.1263/jbb.102.369 (Pubitemid 44781320)
140. JW Wong KH Yuen 2001 Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins Int J Pharm 227 177 85 11564552 1:CAS:528:DC%2BD3MXmvVentbs%3D 10.1016/S0378-5173(01)00796-7 (Pubitemid 32868771)
141. M Usuda T Endo H Nagase K Tomono H Ueda 2000 Interaction of antimalarial agent artemisinin with cyclodextrins Drug Dev Ind Pharm 26 613 9 10826109 1:CAS:528:DC%2BD3cXjt1CjsLs%3D 10.1081/DDC-100101276 (Pubitemid 30317067)
142. X Wen F Tan Z Jing Z Liu 2004 Preparation and study the 1:2 inclusion complex of carvedilol with β-cyclodextrin J Pharm Biom Anal 34 517 23 1:CAS:528:DC%2BD2cXptFehuw%3D%3D 10.1016/S0731-7085(03)00576-4 (Pubitemid 38177341)
143. G Zingone F Rubessa 2005 Preformulation study of the inclusion complex warfarin-β-cyclodextrin Int J Pharm 291 3 10 15707726 1:CAS:528: DC%2BD2MXhtFejtLY%3D 10.1016/j.ijpharm.2004.11.013 (Pubitemid 40221992)
144. IV Terekhova TV Volkova GL Perlovich 2007 Interactions of theophylline with cyclodextrins in water Mendeleev Commun 17 244 6 1:CAS:528: DC%2BD2sXptl2itLc%3D 10.1016/j.mencom.2007.06.022
145. SM Badr-Eldin SA Elkheshen MM Ghorab 2008 Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: Preparation and in-vitro evaluation Eur J Pharm Biopharm 70 819 27 18655829 1:CAS:528:DC%2BD1cXhtlagsL7F 10.1016/j.ejpb.2008.06.024
146. Y Liu G-S Chen Y Chen J Lin 2005 Inclusion complexes of azadirachtin with native and methylated cyclodextrins: solubilization and binding ability Bioorg Med Chem. 13 4037 42 15911316 1:CAS:528:DC%2BD2MXks1Gjsrw%3D 10.1016/j.bmc.2005.03.051 (Pubitemid 40725035)
147. S Petralito I Zanardi A Memoli MC Annesini V Travagli 2009 Solubility, spectroscopic properties and photostability of Rhein/cyclodextrin inclusion complex Spectrochim Acta Part A 74 1254 9 10.1016/j.saa.2009.09.056 1:CAS:528:DC%2BD1MXhtlOksLjK
148. KP Chowdary SV Srinivas 2006 Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl-β-cyclodextrin AAPS PharmSciTech 7 E184 9 10.1208/pt070379 (Pubitemid 44548844)
149. Y He E Tabibi SH Yalkowsky 2006 Solubilization of two structurally related anticancer drugs: XK-469 and PPA J Pharm Sci 95 97 107 16315229 1:CAS:528:DC%2BD28XlvVShtw%3D%3D 10.1002/jps.20500
150. G Gladys G Claudia L Marcela 2003 The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-β-cyclodextrin Eur J Pharm Sci 20 285 93 14592694 10.1016/S0928-0987(03)00202-1 1:CAS:528: DC%2BD3sXosVyltrk%3D (Pubitemid 37338534)